Effects of liraglutide on visceral and ectopic fat in overweight and obese adults at high cardiovascular risk: a randomized, double-blind, placebo-controlled clinical trial
Obesity and Cardiovascular Disease: A Scientific Statement from the American Heart Association.
Circulation. 2021; 143: e984-1010
Trends in obesity and the prevalence of severe obesity among U.S. youth and adults by sex and age, 2007-2008 to 2015-2016.
JAMA. 2018; 319: 1723-1725
Prevalence of obesity and severe obesity in adults: United States, 2017-2018.
NCHS Data Sheet. 2020; 360: 1-8
Fifty Years of Behavioral / Lifestyle Interventions for Overweight and Obesity: Where Are We and Where Are We Going ?.
Obesity (Silver Spring). 2017; 25: 1867-1875
Maintaining long-term weight loss for obesity: a multidisciplinary approach.
Diabetes Metab Syndr Obes. 2016; 9: 37-46
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes.
N Engl J Med. 2013; 369: 145-154
Dysfunctional adiposity and risk of prediabetes and type 2 diabetes in obese adults.
JAMA. 2012; 308: 1150-1159
Distribution of body fat and cardiovascular disease in obese adults.
J Am Coll Cardiol. 2015 ; 65: 2150-2151
Associations of visceral and abdominal subcutaneous adipose tissue with markers of cardiac and metabolic risk in obese adults.
Obesity (Silver Spring). 2013; 21: E439-E447
Visceral and subcutaneous fatty tissue compartments of the abdomen: association with metabolic risk factors in the Framingham Heart Study.
Circulation. 2007; 116: 39-48
Impact of abdominal, visceral and subcutaneous adipose tissue on cardiometabolic risk factors: the Jackson Heart Study.
J Clin Endocrinol Metab. 2010; 95: 5419-5426
Visceral adiposity and the risk of type 2 diabetes: a prospective study in Japanese Americans.
Diabetic treatments. 2000; 23: 465-471
Association of pharmacological treatments for obesity with weight loss and adverse events: a systematic review and meta-analysis.
JAMA. 2016; 315: 2424-2434
2013 AHA / ACC / TOS Guidelines for the Management of Overweight and Obesity in Adults: Report of the American College of Cardiology / American Heart Association Task Force on Practice Guidelines and The Obesity Society.
Circulation. 2014 ; 129: S102-S138
Pharmacological management of obesity: clinical practice guide from the Endocrine Society.
J Clin Endocrinol Metab. 2015 ; 100: 342-362
Effect of exercise and pharmacological interventions on visceral adiposity: a systematic review and meta-analysis of long-term randomized controlled trials.
Mayo Clin Proc. 2019; 94: 211-224
Randomized, placebo-controlled trial of liraglutide on magnetic resonance parameters in people with type 2 diabetes: a pre-specified secondary study on ectopic fat accumulation.
Diabetology. 2020; 63: 65-74
A randomized, double-blind, placebo-controlled trial to evaluate the effect of liraglutide on ectopic fat accumulation in South Asian type 2 diabetic patients.
Cardiovascular Diabetol. 2019; 18: 87
Liraglutide reduces visceral and intrahepatic fat without significant loss of muscle mass in obese patients with type 2 diabetes: a prospective case series.
J Clin Med Res. 2019; 11: 219-224
Liraglutide for weight management: a critical review of the evidence.
Obes Sci Pract. 2017; 3: 3-14
A randomized controlled trial of 3.0 mg of liraglutide in weight management.
N Engl J Med. 2015 ; 373: 11-22
Effectiveness of liraglutide for weight loss in patients with type 2 diabetes: the randomized clinical trial in diabetes SCALE.
JAMA. 2015 ; 314: 687-699
Weight maintenance and additional weight loss with liraglutide after low-calorie diet-induced weight loss: the randomized SCALE Maintenance study.
Int J Obes. 2013; 37: 1443-1451
Liraglutide and cardiovascular results in type 2 diabetes.
N Engl J Med. 2016; 375: 311-322
Reduction of cardiovascular risk with liraglutide: an exploratory mediating analysis of the LEADER trial.
Diabetic treatments. 2020; 43: 1546-1552
Safety, tolerance and sustained weight loss over 2 years with the once-daily human GLP-1 analogue, liraglutide.
Int J Obes. 2012; 36: 843-854
Saxenda from Novo Nordisk remains the best obesity treatment in the world.
Diagnosis and management of metabolic syndrome: a scientific statement from the American Heart Association / National Heart, Lung, and Blood Institute.
Circulation. 2005; 112: 2735-2752
Human energy needs: report of a joint FAO / WHO / UNU expert consultation.
Nutr Bull food. 2005; 26: 166
Feasibility of MRI-based analysis of body composition in large-scale population studies.
PLoS One. 2016; 11e0163332
Validation of a rapid method for quantifying intra-abdominal and subcutaneous adipose tissue for large-scale human studies.
Biomed NMR. 2015 ; 28: 1747-1753
Automatic and quantitative evaluation of regional muscle volume by multi-atlas segmentation using whole body water-fat MRI.
J Magn Reson Imaging. 2015 ; 41: 1558-1569
Accuracy of body composition measurements by MRI of postmenopausal women.
PLoS One. 2018; 13e0192495
Reproducibility and repeatability of MRI body composition analysis.
Magn Reson Med. 2020; 84: 3146-3156
Effects of liraglutide in the treatment of obesity: randomized, double-blind, placebo-controlled study.
Lancet. 2009; 374: 1606-1616
Effects of liraglutide on weight loss, fat distribution and β cell function in obese subjects with prediabetes or early type 2 diabetes.
Diabetic treatments. 2017; 40: 1556-1564
Weight loss with liraglutide, a human glucagon-like peptide-1 analogue given once daily for the treatment of type 2 diabetes as monotherapy or added to metformin, results primarily from reduction in adipose tissue.
Diabetes Obes Metab. 2009; 11: 1163-1172
Semaglutide once a week in overweight or obese adults.
N Engl J Med. 2021; 384: 989-1002
New genetic locus of visceral fat and systemic inflammation.
J Clin Endocrinol Metab. 2019; 104: 3735-3742
Anti-inflammatory therapy with canakinumab for atherosclerotic disease.
N Engl J Med. 2017; 377: 1119-1131
Colchicine in patients with chronic coronary artery disease.
N Engl J Med. 2020; 383: 1838-1847
Liraglutide Treatment Improves Postprandial Lipid Metabolism and Cardiometabolic Risk Factors in Men With Well-Controlled Type 2 Diabetes: A Single-Center Randomized Controlled Study.
Diabetes Obes Metab. 2019; 21: 84-94
GLP-2 deregulates hepatic lipoprotein metabolism, inducing hepatic steatosis and overproduction of VLDL in hamsters and male mice.
Endocrinology. 2018; 159: 3340-3350
Triglycerides and risk reduction of ASCVD: recent perspectives and future directions.
Curr Atheroscler Rep. 2020; 22: 25
Splanchnic lipolysis in human obesity.
J Clin Invest. 2004 ; 113: 1582-1588
Body fat distribution and cardiovascular disease risk: an update.
Circulation. 2012; 126: 1301-1313
Liraglutide in combination with metformin may improve atherogenic lipid profile and decrease C-reactive protein level in statin-treated patients with newly diagnosed coronary heart disease and type 2 diabetes: a randomized trial.
Atherosclerosis. 2019; 288: 60-66
Impact of the analytical approach on the reliability of the MRI assessment of hepatic fat content.
Curr Dev Nutr. 2020; 4nzaa171
Behavioral therapy and sibutramine for the treatment of obesity in adolescents: a randomized controlled trial.
JAMA. 2003; 289: 1805-1812